Patent Validity — § 112(a)
Written Description Requirement
The possession test — separate from enablement, and often the reason broad genus claims fail.
Quick Answer
Under § 112(a), written description requires that the inventor possessed the claimed invention at the time of filing — not just that the specification enables it. The Ariad en banc court (Fed. Cir. 2010) confirmed written description is a separate requirement: broad genus claims fail when the specification describes only a few species without sufficient representative disclosure.
Three § 112 Requirements
Written Description vs. Enablement vs. Definiteness
Written Description
Did the inventor possess the claimed invention at filing?
Standard: Ariad: reasonable conveyance of possession to one skilled in the art
Fails when: Genus with only species examples; new matter in amendments; function without structure
Enablement
Does the specification teach PHOSITA how to make and use?
Standard: Wands factors: undue experimentation? Amgen (S.Ct. 2023) tightened for antibody/genus claims
Fails when: Full scope of genus claims not enabled by limited examples; functional claim lacking structural teaching
Definiteness
Are the claims sufficiently definite to inform the public?
Standard: Nautilus: reasonable certainty to PHOSITA — eliminated 'not amenable to construction' test
Fails when: Terms of degree; subjective terms; conflicting intrinsic record
Genus-Species Problem
Why Broad Claims Fail Written Description
The genus-species written description problem is most acute in biotech and pharma. A patent claiming an entire genus of antibodies, compounds, or molecules must provide written description support for the full scope of the genus, not just a few examples.
Narrow claim (species) — typically passes
- An antibody comprising [specific sequences]
- Compound X having [specific structure]
- A polynucleotide comprising [specific sequence]
Broad genus claim — written description risk
- Any antibody that binds protein X
- A compound that inhibits enzyme Y
- Any sequence encoding function Z
In Ariad Pharmaceuticals v. Eli Lilly (Fed. Cir. 2010 en banc), Ariad's claims covered any compound that reduced NF-κB activity. The specification described the pathway and some hypothetical approaches, but did not describe actual compounds that achieved the result. The en banc court held the claims failed written description — claiming a research program (a goal) is not the same as claiming the invention.
FAQ
What is the written description requirement?
The written description requirement comes from 35 U.S.C. § 112(a), which requires that the specification 'contain a written description of the invention.' In Ariad Pharmaceuticals v. Eli Lilly (Fed. Cir. 2010 en banc), the Federal Circuit confirmed that written description is a separate and distinct requirement from enablement — even a fully-enabled disclosure can fail written description if the inventor has not actually shown possession of the claimed invention. The test: has the inventor demonstrated possession of the claimed invention as of the filing date?
How does written description differ from enablement?
Enablement (§ 112(a)) asks: does the specification teach someone skilled in the art how to make and use the invention without undue experimentation? Written description asks: does the specification show that the applicant actually possessed the claimed invention at the time of filing? An application can fail written description even if enabling — for example, a broad genus claim supported only by a few specific examples may enable the full genus but still fail written description if the inventor hasn't demonstrated possession of the full breadth of the genus. After Amgen v. Sanofi (S.Ct. 2023), enablement for genus claims is itself demanding, but written description remains a separate, independent requirement.
What is the 'possession' test for written description?
The possession test, articulated in Ariad Pharmaceuticals v. Eli Lilly (Fed. Cir. 2010 en banc), asks whether the disclosure 'reasonably conveys to those skilled in the art that the inventor had possession of the claimed subject matter as of the filing date.' Possession is shown by describing the invention with all its limitations — not just a research plan or desired result. For genus claims, the specification must describe representative species sufficient to convey that the applicant 'visualized or recognized' the members of the genus. Broad functional language covering an entire genus without structural support for that genus typically fails.
When do claims fail written description even though the patent application describes something?
Common failure scenarios: (1) Claim amendments during prosecution that add new subject matter not originally disclosed (new matter); (2) Broad genus claims where the specification only exemplifies a few species and doesn't describe enough representative examples to convey possession of the full genus; (3) Claims directed to a result or function rather than a specific structure achieving that result (claiming 'any antibody that binds protein X' without characterizing such antibodies); (4) After-arising claims in continuation applications that claim a different species than was originally disclosed; (5) Claims to a combination of elements where the specification shows them separately but not in combination.
How does written description affect continuation and CIP applications?
For continuation applications, new claims added during prosecution must have written description support in the original application — not just the earlier filing date, but actual support. If a continuation adds claims to subject matter not in the original specification, those claims get only the continuation's own filing date, not the parent's priority date. In continuation-in-part (CIP) applications, each claim must be separately analyzed — claims supported only by the new material added in the CIP get the CIP filing date, making them potentially vulnerable to intervening prior art. Written description analysis is particularly important in CIP prosecutions.
Related Guides